Gastric Cancer
Copyright ©The Author(s) 2003. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 15, 2003; 9(5): 888-893
Published online May 15, 2003. doi: 10.3748/wjg.v9.i5.888
Response of human REV3 gene to gastric cancer inducing carcinogen N-methyl-N’-nitro-N-nitrosoguanidine and its role in mutagenesis
Feng Zhu, Cai-Xia Jin, Tao Song, Jun Yang, Lei Guo, Ying-Nian Yu
Feng Zhu, Tao Song, Jun Yang, Lei Guo, Ying-Nian Yu, Department of Pathophysiology, Zhejiang University School of Medicine, Hangzhou 310031, Zhejiang Province, China
Cai-Xia Jin, Department of Biology, Ningxia Medical College, Yingchuan 750004, Ningxia Self-governing Region, China
Author contributions: All authors contributed equally to the work.
Supported by a grant from the National Natural Science Foundation of China for Key Program, No. 39830210, and a grant from the National Natural Science Foundation of China, No. 39960067, and a grant from National Key Basic Research and Development Program, No. 2002CB512904
Correspondence to: Professor Ying-Nian Yu, Department of Pathophysiology, Zhejiang University School of Medicine, Hangzhou 310031, Zhejiang Province, China. ynyu@mail.hz.zj.cn
Telephone: +86-571-87217149 Fax: +86-571-87217149
Received: December 7, 2002
Revised: December 23, 2002
Accepted: January 13, 2003
Published online: May 15, 2003
Abstract

AIM: To understand the response of human REV3 gene to gastric cancer inducing carcinogen N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) and its role in human mutagenesis.

METHODS: The response of the human REV3 gene to MNNG was measured in human 293 cells and FL cells by RT-PCR. By using antisense technology, mutation analysis at HPRT locus (on which lesion-targeted mutation usually occurs) was conducted in human transgenic cell line FL-REV3- by 8-azaguanine screening, and mutation occurred on undamaged DNA template was detected by using a shuttle plasmid pZ189 as the probe in human transgenic cell lines 293-REV3- and FL-REV3-. The blockage effect of REV3 was measured by combination of reverse transcription-polymerase chain reaction to detect the expression of antisense REV3 RNA and Western blotting to detect the REV3 protein level.

RESULTS: The human REV3 gene was significantly activated by MNNG treatment, as indicated by the upregulation of REV3 gene expression at the transcriptional level in MNNG-treated human cells, with significant increase of REV3 expression level by 0.38 fold, 0.33 fold and 0.27 fold respectively at 6 h, 12 h and 24 h in MNNG-treated 293 cells (P < 0.05); and to 0.77 fold and 0.65 fold at 12 h and 24 h respectively in MNNG-treated FL cells (P < 0.05). In transgenic cell line (in which REV3 was blocked by antisense REV3 RNA), high level of antisense REV3 RNA was detected, with a decreased level of REV3 protein. MNNG treatment significantly increased the mutation frequencies on undamaged DNA template (untargeted mutation), and also at HPRT locus (lesion-targeted mutation). However, when REV3 gene was blocked by antisense REV3 RNA, the MNNG-induced mutation frequency on undamaged DNA templates was significantly decreased by 3.8 fold (P < 0.05) and 5.8 fold (P < 0.01) respectively both in MNNG-pretreated transgenic 293 cells and FL cells in which REV3 was blocked by antisense RNA, and almost recovered to their spontaneous mutation levels. The spontaneous HPRT mutation was disappeared in REV3-disrupted cells, and induced mutation frequency at HPRT locus significantly decreased from 8.66 × 10-6 in FL cells to 0.14 × 10-6 in transgenic cells as well (P < 0.01).

CONCLUSION: The expression of the human REV3 can be upregulated at the transcriptional level in response to MNNG. The human REV3 gene plays a role not only in lesion-targeted DNA mutagenesis, but also in mutagenesis on undamaged DNA templates that is called untargeted mutation.

Keywords: $[Keywords]